Therapies for Type 1 Diabetes: Current Scenario and Future Perspectives

Varun Pathak*, Nupur Madhur Pathak, Christina L. O’Neill, Jasenka Guduric-Fuchs, Reinhold J. Medina

*Corresponding author for this work

Research output: Contribution to journalReview article

1 Citation (Scopus)
40 Downloads (Pure)

Abstract

Type 1 diabetes (T1D) is caused by autoimmune destruction of insulin-producing β cells located in the endocrine pancreas in areas known as islets of Langerhans. The current standard-of-care for T1D is exogenous insulin replacement therapy. Recent developments in this field include the hybrid closed-loop system for regulated insulin delivery and long-acting insulins. Clinical studies on prediction and prevention of diabetes-associated complications have demonstrated the importance of early treatment and glucose control for reducing the risk of developing diabetic complications. Transplantation of primary islets offers an effective approach for treating patients with T1D. However, this strategy is hampered by challenges such as the limited availability of islets, extensive death of islet cells, and poor vascular engraftment of islets post-transplantation. Accordingly, there are considerable efforts currently underway for enhancing islet transplantation efficiency by harnessing the beneficial actions of stem cells. This review will provide an overview of currently available therapeutic options for T1D, and discuss the growing evidence that supports the use of stem cell approaches to enhance therapeutic outcomes.

Original languageEnglish
Number of pages13
JournalClinical Medicine Insights: Endocrinology and Diabetes
Volume12
DOIs
Publication statusPublished - 03 May 2019

Fingerprint

Type 1 Diabetes Mellitus
Islets of Langerhans Transplantation
Islets of Langerhans
Diabetes Complications
Insulin
Stem Cells
Long-Acting Insulin
Therapeutics
Standard of Care
Blood Vessels
Glucose

Keywords

  • endothelial colony forming cells
  • immune therapies
  • induced pluripotent stem cells
  • insulin therapy
  • islet transplant
  • mesenchymal stem cells
  • Type 1 diabetes

Cite this

@article{fdbeb15d2d654cc6a0b3d3887924461a,
title = "Therapies for Type 1 Diabetes: Current Scenario and Future Perspectives",
abstract = "Type 1 diabetes (T1D) is caused by autoimmune destruction of insulin-producing β cells located in the endocrine pancreas in areas known as islets of Langerhans. The current standard-of-care for T1D is exogenous insulin replacement therapy. Recent developments in this field include the hybrid closed-loop system for regulated insulin delivery and long-acting insulins. Clinical studies on prediction and prevention of diabetes-associated complications have demonstrated the importance of early treatment and glucose control for reducing the risk of developing diabetic complications. Transplantation of primary islets offers an effective approach for treating patients with T1D. However, this strategy is hampered by challenges such as the limited availability of islets, extensive death of islet cells, and poor vascular engraftment of islets post-transplantation. Accordingly, there are considerable efforts currently underway for enhancing islet transplantation efficiency by harnessing the beneficial actions of stem cells. This review will provide an overview of currently available therapeutic options for T1D, and discuss the growing evidence that supports the use of stem cell approaches to enhance therapeutic outcomes.",
keywords = "endothelial colony forming cells, immune therapies, induced pluripotent stem cells, insulin therapy, islet transplant, mesenchymal stem cells, Type 1 diabetes",
author = "Varun Pathak and Pathak, {Nupur Madhur} and O’Neill, {Christina L.} and Jasenka Guduric-Fuchs and Medina, {Reinhold J.}",
year = "2019",
month = "5",
day = "3",
doi = "10.1177/1179551419844521",
language = "English",
volume = "12",
journal = "Clinical Medicine Insights: Endocrinology and Diabetes",
issn = "1179-5514",

}

Therapies for Type 1 Diabetes: Current Scenario and Future Perspectives. / Pathak, Varun; Pathak, Nupur Madhur; O’Neill, Christina L.; Guduric-Fuchs, Jasenka; Medina, Reinhold J.

In: Clinical Medicine Insights: Endocrinology and Diabetes, Vol. 12, 03.05.2019.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Therapies for Type 1 Diabetes: Current Scenario and Future Perspectives

AU - Pathak, Varun

AU - Pathak, Nupur Madhur

AU - O’Neill, Christina L.

AU - Guduric-Fuchs, Jasenka

AU - Medina, Reinhold J.

PY - 2019/5/3

Y1 - 2019/5/3

N2 - Type 1 diabetes (T1D) is caused by autoimmune destruction of insulin-producing β cells located in the endocrine pancreas in areas known as islets of Langerhans. The current standard-of-care for T1D is exogenous insulin replacement therapy. Recent developments in this field include the hybrid closed-loop system for regulated insulin delivery and long-acting insulins. Clinical studies on prediction and prevention of diabetes-associated complications have demonstrated the importance of early treatment and glucose control for reducing the risk of developing diabetic complications. Transplantation of primary islets offers an effective approach for treating patients with T1D. However, this strategy is hampered by challenges such as the limited availability of islets, extensive death of islet cells, and poor vascular engraftment of islets post-transplantation. Accordingly, there are considerable efforts currently underway for enhancing islet transplantation efficiency by harnessing the beneficial actions of stem cells. This review will provide an overview of currently available therapeutic options for T1D, and discuss the growing evidence that supports the use of stem cell approaches to enhance therapeutic outcomes.

AB - Type 1 diabetes (T1D) is caused by autoimmune destruction of insulin-producing β cells located in the endocrine pancreas in areas known as islets of Langerhans. The current standard-of-care for T1D is exogenous insulin replacement therapy. Recent developments in this field include the hybrid closed-loop system for regulated insulin delivery and long-acting insulins. Clinical studies on prediction and prevention of diabetes-associated complications have demonstrated the importance of early treatment and glucose control for reducing the risk of developing diabetic complications. Transplantation of primary islets offers an effective approach for treating patients with T1D. However, this strategy is hampered by challenges such as the limited availability of islets, extensive death of islet cells, and poor vascular engraftment of islets post-transplantation. Accordingly, there are considerable efforts currently underway for enhancing islet transplantation efficiency by harnessing the beneficial actions of stem cells. This review will provide an overview of currently available therapeutic options for T1D, and discuss the growing evidence that supports the use of stem cell approaches to enhance therapeutic outcomes.

KW - endothelial colony forming cells

KW - immune therapies

KW - induced pluripotent stem cells

KW - insulin therapy

KW - islet transplant

KW - mesenchymal stem cells

KW - Type 1 diabetes

UR - http://www.scopus.com/inward/record.url?scp=85065238111&partnerID=8YFLogxK

U2 - 10.1177/1179551419844521

DO - 10.1177/1179551419844521

M3 - Review article

AN - SCOPUS:85065238111

VL - 12

JO - Clinical Medicine Insights: Endocrinology and Diabetes

JF - Clinical Medicine Insights: Endocrinology and Diabetes

SN - 1179-5514

ER -